Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine

ABSTRACT

CYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any severity and serotype, serotype specific efficacy, efficacy dependent on baseline seropositivity, efficacy against hospitalizations and efficacy against severe disease. Because of the higher efficacy and the absence of a safety signal, the age group with the best benefit of the use of CYD-TDV is individuals aged 9 and above – the age group for which licensure is now being sought.

KEYWORDS:

• dengue
• vaccine
• efficacy
• age indication
• efficacy

Financial and competing interests disclosure

A Wilder-Smith was the principal investigator of a Phase 2b trial in Singapore before 2010. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.